Clinical Trials Logo

Langerhans Cell Histiocytosis clinical trials

View clinical trials related to Langerhans Cell Histiocytosis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05092815 Active, not recruiting - Clinical trials for Langerhans Cell Histiocytosis

The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation

Start date: December 6, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess safety, efficacy and PK in adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) given HLX208 (BRAF V600E inhibitor).

NCT ID: NCT03220035 Active, not recruiting - Soft Tissue Sarcoma Clinical Trials

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Start date: November 8, 2017
Phase: Phase 2
Study type: Interventional

This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body (advanced) and have come back (recurrent) or do not respond to treatment (refractory). Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02425904 Active, not recruiting - Clinical trials for Langerhans Cell Histiocytosis

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Start date: May 2015
Phase: Phase 2
Study type: Interventional

This research study is evaluating a drug called clofarabine as a possible treatment for Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.